Efficacy of oral moxifloxacin for aerobic vaginitis

European Journal of Clinical Microbiology and Infectious Diseases

Volumn 35, Issue 1, 2016, Pages 95-101

  Wang, C ^a   Han, C ^a   Geng, N ^a   Fan, A ^a   Wang, Y ^a   Yue, Y ^a   Zhang, H ^a   Xue, F ^a  

^a TIANJIN MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CHLORQUINALDOL; CHLORQUINALDOL PROMESTRIENE; MOXIFLOXACIN; PROMESTRIENE; UNCLASSIFIED DRUG; ANTIINFECTIVE AGENT; QUINOLONE DERIVATIVE;

ADULT; AEROBIC VAGINITIS; ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; DIZZINESS; DRUG EFFICACY; DRUG TOLERABILITY; DYSPAREUNIA; FEMALE; FOLLOW UP; GENERAL HOSPITAL; HUMAN; HYPEREMIA; LABORATORY TEST; MAJOR CLINICAL STUDY; NAUSEA; OUTCOME ASSESSMENT; OUTPATIENT; PRIORITY JOURNAL; PROSPECTIVE STUDY; PRURITUS; RASH; RECURRENT INFECTION; STOMACH DISCOMFORT; TREATMENT DURATION; TRICHOMONAS VAGINALIS; VAGINA CANDIDIASIS; VAGINA DISCHARGE; VAGINA PH; VAGINAL BURNING SENSATION; VAGINAL PRURITUS; VAGINITIS; VOMITING; VULVA PRURITUS; ORAL DRUG ADMINISTRATION; PATHOLOGY; PH; PROGNOSIS; TREATMENT OUTCOME; UNIVERSITY HOSPITAL; VAGINA; VAGINOSIS, BACTERIAL; YOUNG ADULT;

ADMINISTRATION, ORAL; ADULT; ANTI-BACTERIAL AGENTS; FEMALE; FLUOROQUINOLONES; HOSPITALS, UNIVERSITY; HUMANS; HYDROGEN-ION CONCENTRATION; PROGNOSIS; PROSPECTIVE STUDIES; TREATMENT OUTCOME; VAGINA; VAGINOSIS, BACTERIAL; YOUNG ADULT;

EID: 84954369669     PISSN: 09349723     EISSN: 14354373     Source Type: Journal    
DOI: 10.1007/s10096-015-2513-8     Document Type: Article

References (23)

1. Donders GG, Vereecken A, Bosmans E, Dekeersmaecker A, Salembier G, Spitz B (2002) Definition of a type of abnormal vaginal flora that is distinct from bacterial vaginosis: aerobic vaginitis. BJOG 109(1):34–43
2. Tansarli GS, Kostaras EK, Athanasiou S, Falagas ME (2013) Prevalence and treatment of aerobic vaginitis among non-pregnant women: evaluation of the evidence for an underestimated clinical entity. Eur J Clin Microbiol Infect Dis 32(8):977–984
3. Donders G, De Wet HG, Hooft P, Desmyter J (1993) Lactobacilli in Papanicolaou smears, genital infections, and pregnancy. Am J Perinatol 10(5):358–361
4. Marconi C, Donders GG, Martin LF, Ramos BR, Duarte MT, Parada CM, Tristão AR, Silva MG (2012) Chlamydial infection in a high risk population: association with vaginal flora patterns. Arch Gynecol Obstet 285(4):1013–1018
5. Donders G, Bellen G, Rezeberga D (2011) Aerobic vaginitis in pregnancy. BJOG 118(10):1163–1170
6. Tempera G, Abbadessa G, Bonfiglio G, Cammarata E, Cianci A, Corsello S, Raimondi A, Ettore G, Nicolosi D, Furneri PM (2006) Topical kanamycin: an effective therapeutic option in aerobic vaginitis. J Chemother 18(4):409–414
7. Sobel JD (1994) Desquamative inflammatory vaginitis: a new subgroup of purulent vaginitis responsive to topical 2% clindamycin therapy. Am J Obstet Gynecol 171(5):1215–1220
8. Fan A, Yue Y, Geng N, Zhang H, Wang Y, Xue F (2013) Aerobic vaginitis and mixed infections: comparison of clinical and laboratory findings. Arch Gynecol Obstet 287(2):329–335
9. Nugent RP, Krohn MA, Hillier SL (1991) Reliability of diagnosing bacterial vaginosis is improved by a standardized method of gram stain interpretation. J Clin Microbiol 29(2):297–301
10. Aroutcheva A, Gariti D, Simon M, Shott S, Faro J, Simoes JA, Gurguis A, Faro S (2001) Defense factors of vaginal lactobacilli. Am J Obstet Gynecol 185(2):375–379
11. Dover SE, Aroutcheva AA, Faro S, Chikindas ML (2008) Natural antimicrobials and their role in vaginal health: a short review. Int J Probiotics Prebiotics 3(4):219–230
12. Hooper DC, Wolfson JS (1991) Fluoroquinolone antimicrobial agents. N Engl J Med 324(6):384–394
13. Tempera G, Furneri PM (2010) Management of aerobic vaginitis. Gynecol Obstet Invest 70(4):244–249
14. Choi SY, Chang CE, Kim SC, So JS (2003) Antimicrobial susceptibility and strain prevalence of Korean vaginal Lactobacillus spp. Anaerobe 9(6):277–280
15. Guay DR (2006) Moxifloxacin in the treatment of skin and skin structure infections. Ther Clin Risk Manag 2(4):417–434
16. Soussy CJ, Nguyen J, Goldstein F, Dabernat H, Andremont A, Leclercq R, Drugeon H, Cavallo P, Chardon H, Etienne J, Rio Y, Courvalin P (2003) In vitro antibacterial activity of moxifloxacin against hospital isolates: a multicentre study. Clin Microbiol Infect 9(10):997–1005
17. Sobottka I, Wegscheider K, Balzer L, Böger RH, Hallier O, Giersdorf I, Streichert T, Haddad M, Platzer U, Cachovan G (2012) Microbiological analysis of a prospective, randomized, double-blind trial comparing moxifloxacin and clindamycin in the treatment of odontogenic infiltrates and abscesses. Antimicrob Agents Chemother 56(5):2565–2569
18. Tempera G, Bonfiglio G, Cammarata E, Corsello S, Cianci A (2004) Microbiological/clinical characteristics and validation of topical therapy with kanamycin in aerobic vaginitis: a pilot study. Int J Antimicrob Agents 24(1):85–88
19. Speciale A, Musumeci R, Blandino G, Milazzo I, Caccamo F, Nicoletti G (2002) Minimal inhibitory concentrations and time-kill determination of moxifloxacin against aerobic and anaerobic isolates. Int J Antimicrob Agents 19(2):111–118
20. Nicolau DP (2001) Predicting antibacterial response from pharmacodynamic and pharmacokinetic profiles. Infection 29(Suppl 2):11–15
21. Thomas J, Linton S, Corum L, Slone W, Okel T, Percival SL (2012) The affect of pH and bacterial phenotypic state on antibiotic efficacy. Int Wound J 9(4):428–435
22. Yang L, Wang K, Li H, Denstedt JD, Cadieux PA (2014) The influence of urinary ph on antibiotic efficacy against bacterial uropathogens. Urology 84(3):731
23. Ball P, Stahlmann R, Kubin R, Choudhri S, Owens R (2004) Safety profile of oral and intravenous moxifloxacin: cumulative data from clinical trials and postmarketing studies. Clin Ther 26(7):940–950